Literature DB >> 15179414

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.

Yasuhiko Ikeda, Kazuo Umemura, Kazunao Kondo, Kaneo Sekiguchi, So Miyoshi, Mitsuyoshi Nakashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15179414     DOI： 10.1016/j.clpt.2004.02.002

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  41 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

3.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

6.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

7.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Authors:  Ina Scholz; Heike Oberwittler; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

8.  Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.

Authors:  K Nomura; Y Fujimoto; Y Kanbayashi; K Ikawa; M Taniwaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-18       Impact factor: 3.267

9.  Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.

Authors:  Bharat Damle; Robert LaBadie; Penelope Crownover; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

Review 10.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.